Therapy of non-small cell lung cancer.
A few regimens can give clinical responses and more prolonged survival to the patients with NSCLC who respond. In addition, there is often a suppression of morbid symptoms in those patients. This is the situation that can be obtained in about 30% of the treated patients and, in addition, the treatment corresponds, from the psychological point of view, to what the patient expects. The toxicity of chemotherapy and the resulting morbidity and mortality can, to a large extent, be controlled by a close clinical follow-up and the use of various techniques of supportive care. Such a surveillance of patients probably explains why administration of planned therapy can be less expensive than palliative care.
Klastersky
J
J
Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Laboratoire d'Investigation Clinique H.J. Tagnon, Belgium.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000523:psychology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000523:psychology / Q000628:therapy*; D018579:Patient Selection; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents